FindTrial
Sign In

Development of blood tests for early detection and treatment monitoring of cervical cancer

Genetic analysis and development of liquid biopsy tests for early detection and treatment monitoring of cervical cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/01/022862
Enrollment
200
Registered
2020-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

None listed

Sponsors

DBT Ramalingaswamy Fellowship
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria includes Patients 18 years old or older with suspicion of cervical cancer referred to Manipal Comprehensive Cancer Center.

Exclusion criteria

Exclusion criteria: Patients diagnosed with inflammatory or haematological disease after the age of 18 will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
1. The primary outcome is to measure the percentage of cervical cancers that can be detected using a liquid biopsy. Samples from follow up timepoints will be useful for analysis of treatment and their prognostic value for success of brachytherapy. 2. Measure recurrence in cervical cancer patients through serial monitoring with liquid biopsies (blood sample). 3. Identification of novel cervical cancer susceptible genes or genetic markers in the Indian population.Timepoint: 0, 3, 6 months. Follow up at 36 months.—

Secondary

MeasureTime frame
Identification of novel cervical cancer susceptible genes or genetic markers in the Indian population.Timepoint: Pretreatment sample—

Countries

India

Contacts

Public ContactRama Rao Damerla

Kasturba Medical College-Manipal

rama.damerla@manipal.edu9989955566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 23, 2026